Posted by Michael Wonder on 14 Jan 2026
Travere Therapeutics announces FDA extends review of sNDA for Filspari (sparsentan) in FSGS
13 January 2026 - Travere Therapeutics announced that today the US FDA has extended the review timeline of its supplemental new drug application for Filspari (sparsentan) in focal segmental glomerulosclerosis.
The new PDUFA target action date is 13 April 2026.
